Purpose: This study aimed to (1) describe longitudinal trends in patient-reported oral adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in patients receiving multidisciplinary oral care during outpatient cancer drug therapy, and (2) evaluate concordance between PRO-CTCAE and clinician-reported CTCAE scores. Methods: Conducted at the Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital (June–December 2023), oral adverse events were assessed using PRO-CTCAE and CTCAE at baseline and every 3 weeks up to 24 weeks. Concordance for dry mouth and oral mucositis was evaluated using paired same-day scores. Results: Among patients receiving multidisciplinary oral care, 85.2% experienced at least one oral adverse event, most commonly dry mouth. Based on PRO-CTCAE, symptoms rated as moderate or higher were reported in fewer than 10% of cases for most items. Notably, over half of patients reported persistent dry mouth of at least mild severity, and 20–30% of other symptoms also remained. These findings suggest that even lower-grade symptoms may persist and affect quality of life. Concordance between PRO-CTCAE and CTCAE was limited, with 31.1% of patients reporting greater dry mouth severity than clinicians documented. Conclusions: Patient-reported oral adverse events, as assessed by PRO-CTCAE, were frequently mild but persistent throughout outpatient chemotherapy, suggesting a cumulative impact on quality of life. Concordance between PRO-CTCAE and clinician-reported CTCAE was limited, indicating that clinician assessments may underestimate symptoms such as dry mouth. These findings underscore the need to integrate patient-reported outcomes into routine oral care.
1 October 2025 in Translational Lung Cancer Research
Background: The phase III PACIFIC trial demonstrated that one year of durvalumab maintenance therapy after concurrent chemoradiotherapy (CCRT) significantly improved overall survival (OS) in unresectable stage III non-small cell lung cancer (NSCLC), reducing the risk of death by 32% compared with observation. Durvalumab therapy administered for up to 12 months is currently the standard of care for patients with locally advanced NSCLC. This study aimed to identify the factors influencing the completion of durvalumab therapy. Methods: This retrospective study analyzed patients who initiated durvalumab therapy for unresectable NSCLC at Niigata University Medical and Dental Hospital between August 2018 and December 2022. Patients who discontinued the treatment for reasons unrelated to disease progression or adverse events were excluded. The patients were divided into durvalumab completion and non-completion groups, and the clinical factors influencing durvalumab completion were analyzed. Results: Among the 65 enrolled patients, 46.2% completed one year of durvalumab maintenance therapy. The completion rate was significantly lower in patients who received low-dose carboplatin as part of CCRT (20% vs. 54%, P=0.04), and higher in patients with adenocarcinoma (P=0.03). Older patients were more frequently treated with low-dose carboplatin CCRT (median age: 78 vs. 66 years, P<0.001). Patients receiving low-dose carboplatin had a significantly shorter time to treatment failure (median: 3.8 months vs. not reached, P=0.002) and tended to have a shorter OS (median: 47 months vs. not reached, P=0.06). Conclusions: Low-dose carboplatin CCRT is associated with lower durvalumab completion rates and worse outcomes, particularly in older patients. Alternative CCRT regimens may warrant consideration, particularly for older patients who are less likely to complete durvalumab maintenance.
Background: Durvalumab maintenance following concurrent chemoradiotherapy (CCRT) is the standard treatment for unresectable stage III non‐small cell lung cancer (NSCLC); however, some patients discontinue treatment before completing 12 months. We explored whether pretreatment peripheral blood inflammatory and nutritional markers are associated with durvalumab non‐completion. Methods: We retrospectively reviewed patients with locally advanced NSCLC who initiated durvalumab between August 2018 and April 2024. Laboratory data obtained within 7 days before the first dose were analyzed. Completion was defined as 12 months (365 days) of treatment. Routine laboratory parameters and inflammatory/nutritional indices were compared between completers and non‐completers. Exploratory multivariable logistic regression and clinically adjusted sensitivity analyses were performed. Results: Eighty patients were included: 36 completers and 44 non‐completers. Durvalumab was discontinued because of disease progression ( n = 24), radiation pneumonitis ( n = 14), immune‐related adverse events ( n = 5), and aspiration pneumonia ( n = 1). Conventional inflammatory indices did not differ between groups. In the primary exploratory multivariable model, a higher albumin‐to‐globulin (A/G) ratio was associated with durvalumab completion (OR, 9.74; 95% CI, 1.01–93.9; p = 0.048), whereas RDW‐SD showed a non‐significant inverse association with completion (OR, 0.942; 95% CI, 0.883–1.01; p = 0.076). After adjustment for age, ECOG performance status, and histology, these associations were not statistically significant. Conclusions: Lower A/G ratio and higher RDW‐SD before durvalumab initiation may be associated with non‐completion. Given the exploratory design, limited sample size, attenuation after clinical adjustment, and heterogeneous reasons for discontinuation, these findings require external validation.